FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1662 October 18, 2007 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lewis, J. D. Related Article by Sandborn, W. J. Related Article by Schreiber, S. PubMed Citation

To the Editor: With regard to the editorial by Lewis (July 19 issue),¹ the "perfect clinical trial" for Crohn's disease should be generalizable and should predict effectiveness and the benefit-to-risk ratio in practice. Lewis acknowledges that the remission rate at 6 weeks (absolute Crohn's Disease Activity Index [CDAI] score, 150) was low (22% among patients receiving certolizumab pegol vs. 17% among patients receiving placebo, P=0.17) at 26 weeks in the Pegylated Antibody Fragment Evaluation in Crohn's Disease: Safety and Efficacy 1 (PRECISE 1) trial.² However, there is insufficient discussion of the prediction of effectiveness in practice with the primary end . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.